Press Releases

Date Title and Summary Additional Formats
Toggle Summary Retrophin Announces Agreement to Acquire Orphan Technologies
Agreement a dd s OT-58, a novel enzyme replacement therapy in Phase 1/2 development for the treatment of classical homocystinuria Compelling strategic fit that will expand p ipeline of potential first-in-class therapies targeting rare diseases Retrophin to host conference call and webcast today at
View HTML
Toggle Summary Retrophin to Report Third Quarter 2020 Financial Results
SAN DIEGO , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report third quarter 2020 financial results on Thursday, November 5, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Oct. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on October 10, 2020 , the Compensation Committee of its Board of Directors granted inducement equity grants covering an aggregate of 58,750 shares of its common stock to four new employees, consisting
View HTML
Toggle Summary Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
SAN DIEGO , Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET
View HTML
Toggle Summary Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Topline data from 36-week proteinuria endpoint anticipated in third quarter of 2021 SAN DIEGO , Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of
View HTML
Toggle Summary Retrophin, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (Nasdaq: RTRX) today announced that on September 10, 2020 , the Compensation Committee of its Board of Directors granted inducement stock options to purchase an aggregate of 38,250 shares of its common stock to four new employees and
View HTML
Toggle Summary Retrophin President and Chief Executive Officer Eric Dube Named to the 2020 PharmaVOICE 100
SAN  DIEGO (August 3, 2020) – Retrophin,  Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., president  and chief  executive officer, has been named by PharmaVOICE magazine to the 2020 PharmaVOICE 100 – an award that recognizes the 100 Most Inspiring People in the life sciences industry.
View HTML
Toggle Summary Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO , Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following upcoming virtual investor conferences in August: William Blair Biotech Focus Conference 2020 Date: Thursday, August 6, 2020 Time: 3:00 p.m.
View HTML
Toggle Summary Retrophin Reports Second Quarter 2020 Financial Results
Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now anticipated in 2021 Net product sales increased eight percent to $48 million in the second quarter Cash & equivalents of $457 million following
View HTML
Toggle Summary Retrophin to Report Second Quarter 2020 Financial Results
SAN DIEGO , July 16, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML